Blood clots, or venous thromboembolism, remains a leading causes of death and healthcare spending in patients with cancer.
A recently published study aimed to determine the trends in annual rates of hospital admissions related to venous thromboembolism (VTE), as well as the associated cost, length of stay (LOS), and in-hospital mortality in patients with Philadelphia-negative myeloproliferative neoplasms (MPNs), including polycythemia vera (PV), essential thrombocytosis (ET), and primary myelofibrosis (MF).
These patients have a significant risk of VTE, said researchers. Up to one-third of patients with MPN develop VTE, and this has led to development of recommendations of risk-adapted strategies to decrease the thromboembolism rate. However, VTE remains a leading causes of death and healthcare spending in patients with cancer.
In this study, researchers identified patients with PV, ET, and MF from the Nationwide Inpatient Sample (NIS) database from 2006 to 2014.
Hospitalizations where VTE was among the top-3 diagnoses were considered VTE-related. In-hospital outcomes between VTE and non-VTE hospitalizations were compared using chi-square and Mann-Whitney U-test; linear regression was used for trend analysis.
The authors identified 1,046,666 admissions with a diagnosis of MPN. The majority of patients were white (65.6%) and female (52.7%), with a median age of 66 years. ET was the most common MPN (54%).
There was no difference in in-hospital mortality between groups (VTE: 3.4% vs. non-VTE: 3.2%; P  = .12); however, VTE admissions had a longer LOS (median: 6 vs. 5 days; P < .01) and higher cost (median: VTE $32,239 vs. $28,403; P ≤ .01).
The annual rate of VTE admissions decreased over time (2006: 3.94% vs. 2014: 2.43%; P ≤.01), compared with non-VTE-related admissions.
Researchers found that VTE-related admissions had similar in-hospital mortality as compared with non-VTE-related admissions. Hospitalization rates due to VTE have decreased over time but are linked to higher cost and LOS. Newer risk assessment tools may assist in preventing VTE in high-risk patients and optimizing resource utilization.
Reference
Katiyar V, Uprety A, Mendez-Hernandez A, Fuentes HE, Andrade XA, Zia M. Trends and inpatient outcomes of venous thromboembolism-related admissions in patients with Philadelphia-negative myeloproliferative neoplasms [published July 17, 2019]. doi: 10.1055/s-0039-1692988
NCCN Guidelines Update Adds Momelotinib Below Ruxolitinib for High-, Low-Risk Myelofibrosis
January 23rd 2024Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia. However, ruxolitinib retains a higher category of recommendation as a treatment for patients with MF.
Read More
Oncology Onward: A Conversation With Dr Shereef Elnahal, Under Secretary for Health
April 20th 2023Shereef Elnahal, MD, MBA, under secretary for health at the Veterans Health Administration (VHA), sat for a conversation with our hosts Emeline Aviki, MD, MBA, Memorial Sloan Kettering Cancer Center, and Stephen Schleicher, MD, MBA, Tennessee Oncology, that covered the cancer footprint of the VHA.
Listen
Interventions Needed to Increase DMT Uptake in Sickle Cell Disease
December 26th 2023A recent study found that uptake of disease-modifying therapies (DMTs) has been low among patients with sickle cell disease, suggesting that more interventions that consider individual patient characteristics are needed to improve adoption.
Read More
Exploring Payer Coverage Decisions Following FDA Novel Drug Approvals
May 3rd 2022On this episode of Managed Care Cast, Ari D. Panzer, BS, lead author and researcher, then at Tufts Medical Center—now at Duke University—discusses the findings from his team’s investigation into coverage decisions by health plan insurers of the 66 drugs approved by the FDA in 2018.
Listen
Exagamglogene Autotemcel Meets End Points in Severe Sickle Cell Disease, β-Thalassemia
December 7th 2023Two posters set to be presented at the 65th American Society of Hematology Annual Meeting & Exposition met their primary and secondary end points regarding exagamglogene autotemcel therapy for sickle cell disease and β-thalassemia.
Read More
NCCN Guidelines Update Adds Momelotinib Below Ruxolitinib for High-, Low-Risk Myelofibrosis
January 23rd 2024Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia. However, ruxolitinib retains a higher category of recommendation as a treatment for patients with MF.
Read More
Oncology Onward: A Conversation With Dr Shereef Elnahal, Under Secretary for Health
April 20th 2023Shereef Elnahal, MD, MBA, under secretary for health at the Veterans Health Administration (VHA), sat for a conversation with our hosts Emeline Aviki, MD, MBA, Memorial Sloan Kettering Cancer Center, and Stephen Schleicher, MD, MBA, Tennessee Oncology, that covered the cancer footprint of the VHA.
Listen
Interventions Needed to Increase DMT Uptake in Sickle Cell Disease
December 26th 2023A recent study found that uptake of disease-modifying therapies (DMTs) has been low among patients with sickle cell disease, suggesting that more interventions that consider individual patient characteristics are needed to improve adoption.
Read More
Exploring Payer Coverage Decisions Following FDA Novel Drug Approvals
May 3rd 2022On this episode of Managed Care Cast, Ari D. Panzer, BS, lead author and researcher, then at Tufts Medical Center—now at Duke University—discusses the findings from his team’s investigation into coverage decisions by health plan insurers of the 66 drugs approved by the FDA in 2018.
Listen
Exagamglogene Autotemcel Meets End Points in Severe Sickle Cell Disease, β-Thalassemia
December 7th 2023Two posters set to be presented at the 65th American Society of Hematology Annual Meeting & Exposition met their primary and secondary end points regarding exagamglogene autotemcel therapy for sickle cell disease and β-thalassemia.
Read More
2 Commerce Drive
Cranbury, NJ 08512